Dirlei Nico Selected Research

N-Glycosyl Hydrolases

1/2019	The F1F3 Recombinant Chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and Its Epitopes Induce Cross-Protection Against Leishmania (V.) braziliensis Infection in Mice.
1/2017	F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis.
1/2017	Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.
1/2017	A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection.
1/2014	Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dirlei Nico Research Topics

Disease

13	Infections 01/2021 - 03/2006
12	Visceral Leishmaniasis (Kala Azar) 01/2020 - 03/2006
6	Leishmaniasis 01/2020 - 11/2010
4	Cutaneous Leishmaniasis 01/2020 - 01/2014
2	Human Influenza (Influenza) 01/2021 - 01/2013
2	Influenza in Birds (Avian Flu) 01/2021 - 01/2015
1	Neglected Diseases 01/2020
1	Bites and Stings (Sting) 01/2020
1	Malaria 01/2020
1	Protozoan Infections 01/2020
1	Nervous System Diseases (Neurological Disorders) 01/2018
1	Zika Virus Infection 01/2018
1	Splenomegaly 01/2017
1	Parasitic Diseases (Parasitic Disease) 01/2017
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 02/2015
1	Dog Diseases (Disease, Canine) 08/2008

Drug/Important Bio-Agent (IBA)

10	VaccinesIBA 01/2021 - 03/2006
6	AntigensIBA 01/2018 - 03/2006
5	N-Glycosyl HydrolasesIBA 01/2019 - 01/2014
4	Immunoglobulin G (IgG)IBA 01/2019 - 02/2015
3	EpitopesIBA 01/2019 - 01/2017
3	CytokinesIBA 01/2017 - 02/2015
3	Fluorometholone (FML)FDA Link 05/2012 - 03/2006
3	SaponinsIBA 05/2012 - 03/2006
2	AntibodiesIBA 01/2018 - 02/2015
2	Combined VaccinesIBA 01/2014 - 11/2010
1	1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA 01/2020
1	Immunoglobulin A (IgA)IBA 01/2019
1	ChemokinesIBA 01/2018
1	GD3 ganglioside (GD(3))IBA 01/2018
1	AutoantibodiesIBA 01/2018
1	GangliosidesIBA 01/2018
1	GlycolipidsIBA 01/2018
1	Interleukin-10 (Interleukin 10)IBA 01/2017
1	Interleukin-17 (Interleukin 17)IBA 01/2017
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017
1	Meglumine AntimoniateIBA 12/2015
1	Pharmaceutical PreparationsIBA 12/2015
1	LeukosialinIBA 02/2015
1	Hemagglutinins (Hemagglutinin)IBA 01/2015
1	Neuraminidase (Sialidase)IBA 01/2015
1	Bradykinin B2 ReceptorIBA 11/2012
1	GTP-Binding Proteins (G-Protein)IBA 11/2012
1	BradykininIBA 11/2012
1	Synthetic Vaccines (Recombinant Vaccines)IBA 08/2008
1	saponin QA-21V1 (QS21)IBA 08/2008
1	DNA VaccinesIBA 08/2008
1	Glycoproteins (Glycoprotein)IBA 08/2008

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 01/2020 - 01/2015
2	Immunotherapy 01/2018 - 01/2014
1	Therapeutics 12/2015